Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE)

Next Previous
Trial Profile

A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edoxaban (Primary) ; Enoxaparin sodium; Heparin; Low molecular weight heparins; Warfarin
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms Hokusai-VTE
  • Sponsors Daiichi Sankyo Inc

Most Recent Events

  • 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
  • 08 Jun 2021 Results obtaining the outcomes from CARAVAGGIO, HOKUSAI-VTE, ADAM VTE and SELECT-D and analysing Cost-effectiveness of apixaban versus other direct oral anticoagulants and low-molecular-weight-heparins for cancer associated venous thromboembolism, presented at the 57th Annual Meeting of the American Society of Clinical Oncology
  • 04 Dec 2018 Results of post hoc analysis evaluating the risk of recurrent VTE during anticoagulation with heparin, edoxaban or warfarin and to identify predictors of recurrence, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top